Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1617 1622 1623 1627
This examiner grants 31% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17513383 | PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOF | Final Rejection | Mitsubishi Tanabe Pharma Corporation |
| 17332431 | COMPOSITIONS AND METHODS FOR DELIVERING THERAPEUTIC AGENTS INTO THE COLON | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 19253120 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Final Rejection | Travere Therapeutics, Inc. |
| 17274950 | ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS | Final Rejection | PURDUE RESEARCH FOUNDATION |
| 17616248 | NOVEL SPIROBICYCLIC INTERMEDIATES | Non-Final OA | Janssen Pharmaceutica NV |
| 18458702 | PERSONAL CARE COMPOSITIONS | Non-Final OA | Colgate-Palmolive Company |
| 17766728 | External Preparation for Treating Epilepsy or Autism Spectrum Disorder | Final Rejection | OSAKA UNIVERSITY |
| 18826821 | TOBACCO HARM REDUCTION AND PAIN RELIEF PRODUCTS AND METHODS THEREOF | Non-Final OA | Ready Mix Naturals, LLC |
| 17772374 | COMPOSITION FOR SLEEP IMPROVEMENT COMPRISING ERGOTHIONEINE OR SALT THEREOF | Non-Final OA | SUNTORY HOLDINGS LIMITED |
| 18429719 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | Non-Final OA | APPLIED THERAPEUTICS, INC. |
| 17715401 | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF PHOSPHOMANNOMUTASE 2 DEFICIENCY | Final Rejection | Applied Therapeutics, Inc. |
| 18365019 | OPHTHALMIC COMPOSITION COMPRISING AN ANTI-ALLERGEN AND A REDNESS REDUCTION AGENT | Non-Final OA | Bausch + Lomb Ireland Limited |
| 17783220 | PARASITE CONTROL IN RUMINANTS | Non-Final OA | Intervet Inc. |
| 18411245 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | Final Rejection | CHEMOCENTRYX, INC. |
| 18022982 | PHARMACEUTICAL COMPOSITION OF SINGLE DOSAGE FORM FOR TREATING OR PREVENTING HYPERTENSION AND HYPERLIPIDEMIA | Final Rejection | Daewoong Pharmaceutical Co., Ltd. |
| 18568590 | USE OF THYROID HORMONE T4 IN A HIGH VERSATILITY TREATMENT IN PATIENTS TAKING PROTON PUMP INHIBITORS | Non-Final OA | IBSA INSTITUT BIOCHIMIQUE SA |
| 18284941 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | Non-Final OA | NIPPON SHINYAKU CO., LTD. |
| 17996272 | TREATMENT OF HYPOTHALAMIC OBESITY | Final Rejection | Saniona A/S |
| 18285021 | ORAL GEL COMPOSITION AND USE THEREOF | Non-Final OA | DR. KURT WOLFF GMBH & CO. KG |
| 18284367 | SELECTIVE MTORC2 INHIBITOR AND USES THEREOF | Non-Final OA | ALIAD BIOPHARMA |
| 17603886 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 17530402 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | Final Rejection | Bayer Pharma Aktiengesellschaft |
| 18130261 | METHODS AND COMPOSITIONS FOR REDUCING OXIDATIVE STRESS | Non-Final OA | Ojai Energetics PBC |
| 17319882 | Compositions And Methods For Reducing Food Cravings | Final Rejection | Nalpropion Pharmaceuticals LLC |
| 17911429 | OPHTHALMIC CHLOROPROCAINE GEL HAVING IMPROVED FUNCTIONALITY | Final Rejection | SINTETICA S.A. |
| 17632841 | CHOLECALCIFEROL FOR USE IN THE TREATMENT OF CELIAC DISEASE | Final Rejection | ABIOGEN PHARMA S.P.A. |
| 18189741 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF TISSUE INJURY | Final Rejection | MedRegen, LLC |
| 18020202 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING NEURODEGENERATION | Non-Final OA | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER |
| 18019219 | PROFILIN1:ACTIN INHIBITOR AS AN ANTI-ANGIOGENIC COMPOUND | Non-Final OA | INSERM(Institut National de la Sante et de la Recherche Medicale) |
| 18005976 | PDE3 inhibitors for treating viral infections | Non-Final OA | Breakthrough Medical Research B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy